Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients-Reference-Cited by-同舟云学术

Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients

Published:2021-10 Issue: Volume:231 Page:108828
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Mathi Kavita,Rosenberg-Hasson Yael,Maecker Holden,Carlo Dennis J.,Moss Ronald B.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference25 articles.

1. Immunology of COVID-19: current state of the science;Vabret;Immunity.,2020

2. An inflammatory cytokine signature predicts COVID-19 severity and survival;Del Valle;Nat. Med.,2020

3. Biomarkers associated with COVID-19 disease progression;Ponti;Crit. Rev. Clin. Lab. Sci.,2020

4. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19;Herold;J. Allergy Clin. Immunol.,2020

5. Autoimmune and inflammatory diseases following COVID-19;Galeotti;Nat. Rev. Rheumatol.,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bile acids and coronavirus disease 2019;Acta Pharmaceutica Sinica B;2024-05

2. Tempol alleviates acute lung injury by affecting glutathione synthesis through Nrf2 and inhibiting ferroptosis in lung epithelial cells;Journal of Biochemical and Molecular Toxicology;2024-03

3. Novel antioxidant protein target therapy to counter the prevalence and severity of SARS-CoV-2;Frontiers in Immunology;2024-01-03

4. Smart stimuli-responsive drug delivery systems in spotlight of COVID-19;Asian Journal of Pharmaceutical Sciences;2023-11

5. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities;Heliyon;2023-02